Heterocyclic Compounds for Immune Response, Cancer Treatment
Summary
The USPTO has published patent application US20260109694A1, filed September 23, 2025 (Application No. 19337361), by inventors Liansheng Li and Pingda Ren. The application covers heterocyclic compounds and pharmaceutical compositions designed to potentiate immune response and treat cancer and other diseases. The compounds are classified under multiple CPC codes including C07D 417/10 and A61K 31/4439.
This publication represents the initial public disclosure of the patent application following USPTO examination. Patent applications are informational documents that do not grant enforceable rights until a patent issues after substantive examination. Pharmaceutical and biotechnology entities developing immunotherapies or cancer treatments should monitor this application for potential IP overlap with their own compounds or therapeutic approaches.
“The subject compositions and methods are particularly useful for potentiating immune response and/or for treating cancer and other diseases.”
About this source
USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.
What changed
The USPTO has published patent application US20260109694A1, filed September 23, 2025 (Application No. 19337361), by inventors Liansheng Li and Pingda Ren. The application covers heterocyclic compounds and pharmaceutical compositions designed to potentiate immune response and treat cancer and other diseases. The compounds are classified under multiple CPC codes including C07D 417/10 and A61K 31/4439.
This publication represents the initial public disclosure of the patent application following USPTO examination. Patent applications are informational documents that do not grant enforceable rights until a patent issues after substantive examination. Pharmaceutical and biotechnology entities developing immunotherapies or cancer treatments should monitor this application for potential IP overlap with their own compounds or therapeutic approaches.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HETEROCYCLIC COMPOUNDS AND USES THEREOF
Application US20260109694A1 Kind: A1 Apr 23, 2026
Inventors
Liansheng Li, Pingda Ren
Abstract
The present disclosure provides compounds and pharmaceutical compositions comprising the same. The compounds, pharmaceutical compositions thereof, and methods of using the same have a range of utilities as therapeutics, diagnostics, and research tools. The subject compositions and methods are particularly useful for potentiating immune response and/or for treating cancer and other diseases.
CPC Classifications
C07D 417/10 A61K 31/433 A61K 31/4439 A61K 31/454 C07D 285/10 C07D 417/12 C07D 487/04
Filing Date
2025-09-23
Application No.
19337361
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.